Dialab ZJG Biotech Completes Nearly RMB 100 Million Series A Financing to Advance Autoimmune and Neurological Diagnostic Product Portfolio

VCBeat Exclusively Learns: Dialab ZJG biotech Co., Ltd. (hereinafter referred to as “Dialab”) Announces Completion of Strategic Series A Financing of Nearly RMB 100 Million. This round was led by Shanghai Changjiang Guohong Investment Management Co., Ltd., with participation from Shulan Junjie Capital, Zhangjiagang Jinmao Venture Capital Co., Ltd., Zhangjiagang Talent No. 1 Fund, and Zhangjiagang Bonded Area Wisdom Venture Capital Co., Ltd.

The funds raised will be used for new product research and development, capacity expansion, and accelerating clinical trials, thereby providing robust support for offering a comprehensive portfolio of laboratory tests for autoimmune and neurological diseases to the clinic and for implementing our internationalization strategy.

Dialab, established in 2016, is dedicated to the research and development of laboratory diagnostic products for autoimmune diseases and neurological disorders. With R&D centers located in Shanghai and Zhangjiagang, Jiangsu Province, it is one of the few manufacturers in China that master the core raw materials and key technologies for laboratory diagnostic products targeting autoantibodies and neurological biomarkers.

Dialab has applied the Nobel Prize-winning technology of "click chemistry" to the preparation of test kits for anti-cardiolipin antibodies and other analytes, and has been granted national invention patents. To date, it has completed the development of nearly 100 laboratory testing products for autoimmune and neurological diseases, obtained over 40 registration certificates for chemiluminescence products, and secured multiple registration certificates for single-use, rapid, quantitative autoimmune diagnostic products, filling gaps both domestically and internationally. This has played a positive role in facilitating the rapid quantitative detection of autoantibodies in laboratories and clinical settings at all levels.

Recently, Dialab ZJG biotech Co., Ltd. successfully obtained seven Class II medical device registration certificates for autoimmune reagents.

It is understood that the Dialab team has been continuously tackling cutting-edge technologies for the expression and purification of transmembrane receptor proteins, ion channel proteins, and small-molecule transmembrane transporters involved in neural signaling pathways, thereby filling the market gap in core raw materials for laboratory testing of autoimmune neurological diseases. The highly sensitive nervous system disease detection system under development will further break through the sensitivity limitations imposed by the “blood-brain barrier” (fg/mL), enabling the detection of neurological biomarkers in blood samples. This technology can be widely applied to the early diagnosis and therapeutic monitoring of autoimmune neurological diseases, cerebrovascular diseases, neurological trauma, and neurodegenerative disorders.

Regarding this round of financing,Gu Yue, Founder of DialabThis round of financing has garnered full trust from professional investment institutions, including Changjiang Guohong and Shulan Junjie, as well as local industrial funds such as Zhangjiagang Jinmao Venture Capital, the Talent Fund of Funds, and Wisdom Venture Capital. Dialab is committed to deepening its expertise in the research, development, and production of laboratory diagnostic products for autoimmune and neurological diseases. The company provides commercialized, quantitative, automated, and high-sensitivity laboratory testing solutions to facilitate the diagnosis of previously difficult-to-identify and differentiate diseases, thereby helping to determine their etiologies and pathogenic mechanisms.

Yu Bojie, Investment Director of Changjiang GuohongStatement: Dialab is one of the few domestic manufacturers mastering core raw materials and technologies for autoimmune diseases. It is poised to break the import monopoly on raw materials and diagnostic reagents in the fields of routine autoimmune and neurological disorders, thereby addressing clinical pain points associated with traditional detection methods, such as operational complexity, inability to provide precise quantification, and failure to deliver effective diagnostic results. Rarely found is a team that possesses both strong R&D capabilities and product commercialization expertise, backed by extensive experience in market promotion and sales. Shanghai Changjiang Guohong Investment Management Co., Ltd. is committed to optimizing resource allocation, facilitating corporate growth, and cultivating industry leaders with international competitiveness. We are honored to partner with Dialab and look forward to growing together, witnessing how the company’s products continue to address unmet clinical needs, benefit patients and society, and establish Dialab as a leading enterprise in the industry.

Shanghai Changjiang Guohong Investment Management Co., Ltd. is a professional management firm specializing in private equity investment. Since its inception in 2012, the company has been committed to becoming a boutique investment management institution that earns investors’ trust, creates value for portfolio companies, and delivers consistent, reasonable returns to investors. Guided by its mission to optimize resource allocation, support corporate growth, and cultivate industry leaders with international competitiveness, Changjiang Guohong focuses deeply on three core sectors: healthcare, intelligent manufacturing, and digital technology. Among the companies invested in by its funds, many have successfully achieved public listings, including Shuanghuan Driveline, Zhengzhou Coal Mining Machinery Group, Buchang Pharma, Longsheng Technology, Weita Industry, Pharmablock, Jiean High-Tech, Haoyuan Chemexpress, Xinwei Medical, Dataway Spectrum, Univ-Bio, Hechuan Technology, and Rongxin Culture.

Shulan Junjie Capital was jointly established by early investors and the founding team of Shulan Medical, leveraging clinical resources on a global scale to facilitate the translation of medical technologies. The fund focuses on three key clinical application scenarios—precision diagnostics, innovative therapies, and research services—and specializes in early-stage investments in high-growth-potential projects within the fields of medical technology and life sciences. Since the establishment of its first fund in 2017, it has supported the rapid early growth of more than thirty startups in areas such as digital technology, omics, gene technology, cell technology, and biomaterials for clinical translation, with the cumulative valuation of its portfolio exceeding RMB 10 billion.

Zhangjiagang Jinmao Venture Capital Co., Ltd. is an investment platform under Zhangjiagang Innovation Investment Group Co., Ltd. With the goals of empowering the industrial economy, leveraging capital, and promoting institutional innovation, and with the mission of facilitating the development of innovative clusters in the technology industry, the Group focuses on Zhangjiagang City’s “4+4” key industrial chains. It aims to build a full-lifecycle technology industry investment system, create a diversified industrial finance ecosystem, optimize its investment structure, enhance its investment capabilities, empower regional technological and industrial innovation, and lead regional industrial transformation and upgrading. Its core businesses focus on technology-oriented investment promotion, the construction and operation of technology industrial parks, the development and management of innovation carriers, technology financial services, private equity investment, and venture capital management. Through market-oriented, specialized, and branded operations, it strives to establish a first-class platform for investment in technological and industrial innovation.

Zhangjiagang Talent No. 1 FundIt is the first talent fund established by Suzhou municipal state-owned enterprises and local governments, with a total scale of RMB 1.5 billion, including an initial scale of RMB 250 million. The fund was jointly initiated by Suzhou Asset Management Co., Ltd., Suzhou Agricultural Development Group, and Zhangjiagang’s municipal, district, and town-level entities. It will link more social capital and project resources, gather more talent projects and technology investment promotion projects, and accelerate empowerment for the construction of the Gangcheng innovation cluster!

Zhangjiagang Bonded Area Wisdom Venture Capital Co., Ltd. closely aligns with the core mission of promoting technological industrialization within the Bonded Area, actively providing investment and financing services to accelerate the industrialization and capitalization of technology- and talent-driven enterprises. Its investment portfolio covers key sectors supported by the Bonded Area, including new materials, new energy, new equipment, and the new economy, gradually establishing itself as the investment and financing platform for the technological incubation sector in Zhangjiagang Bonded Area.